Trastuzumab-related cardiotoxicity: Calling into question the concept of reversibility

Journal of Clinical Oncology

Volumn 25, Issue 23, 2007, Pages 3525-3533

  Telli, Melinda L ^a   Hunt, Sharon A ^a   Carlson, Robert W ^a   Guardino, Alice E ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBOPLATIN; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; NAVELBINE; PACLITAXEL; TAXANE DERIVATIVE; TRASTUZUMAB;

ADJUVANT THERAPY; BREAST CANCER; CARDIOTOXICITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; DRUG DESIGN; DRUG EFFICACY; DRUG WITHDRAWAL; HEART ARRHYTHMIA; HEART FUNCTION; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE ISCHEMIA; HUMAN; METASTASIS; MULTIPLE CYCLE TREATMENT; NONHUMAN; PRIORITY JOURNAL; RADIOISOTOPE VENTRICULOGRAPHY; REVIEW;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS; DRUG TOXICITY; FEMALE; FOLLOW-UP STUDIES; HEART; HEART DISEASES; HEART FAILURE, CONGESTIVE; HUMANS; MIDDLE AGED; VENTRICULAR DYSFUNCTION, LEFT;

EID: 34548152541     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.11.0106     Document Type: Review

References (26)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2006. CA Cancer J Clin 56:106-130, 2006
2. Yarden Y: Biology of HER2 and its importance in breast cancer. Oncology 61:1-13, 2001 (suppl 2)
3. Slamon DJ, Godolphin W, Jones LA, et al: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712, 1989
4. Owens MA, Horten BC, Da Silva MM: HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer 5:63-69, 2004
5. Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182, 1987
6. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001
7. Romond EH, Perez EA, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673-1684, 2005
8. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659-1672, 2005
9. Slamon DJ, Eiermann W, Robert N, et al: Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2-positive early breast cancer patients: BCIRG 006 study. Breast Cancer Res Treat 94:S5, 2005 (abstr)
10. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al: Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 354:809-820, 2006
11. Seidman A, Hudis C, Pierri MK, et al: Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 20:1215-1221, 2002
12. Erickson SL, O'Shea KS, Ghaboosi N, et al: ErbB3 is required for normal cerebellar and cardiac development: A comparison with erbB2-and heregulin-deficient mice. Development 124:4999-5011, 1997
13. Lee KF, Simon H, Chen H, et al: Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature 378:394-398, 1995
14. Crone SA, Zhao YY, Fan L, et al: erbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 8:459-465, 2002
15. Chien KR: Herceptin and the heart: A molecular modifier of cardiac failure. N Engl J Med 354:789-790, 2006
16. Chetlin MD, Armstrong WF, Aurigemma GP, et al: ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography: Summary article - A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). Circulation 108:1146-1162, 2003
17. van Royen N, Jaffe CC, Krumholz HM, et al: Comparison and reproducibility of visual echocardiographic and quantitative radionuclide left ventricular ejection fractions. Am J Cardiol 77:843-850, 1996
18. Naik MM, Diamond GA, Pai T, et al: Correspondence of left ventricular ejection fraction determinations from two-dimensional echocardiography, radionuclide angiography and contrast cineangiography. J Am Coll Cardiol 25:937-942, 1995
19. Bellenger NG, Burgess MI, Ray SG, et al: Comparison of left ventricular ejection fraction and volumes in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance: Are they interchangeable? Eur Heart J 21:1387-1396, 2000
20. Tan-Chiu E, Yothers G, Romond E, et al: Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 23:7811-7819, 2005
21. Perez E, Suman VJ, Davidson NE, et al: Exploratory Analysis from NCCTG N9831: Do clinical characteristics predict cardiac toxicity of trastuzumab when administered as a component of adjuvant therapy? Presented at San Antonio Breast Cancer Symposium, December 8-12, 2005, San Antonio, TX
22. HERA Study Team: Trastuzumab (H: Herceptin) following adjuvant chemotherapy (CT) significantly improves disease-free survival (DFS) in early breast cancer (BC) with HER2 overexpression: The HERA Trial. Presented at San Antonio Breast Cancer Symposium, December 8-12, 2005, San Antonio, TX (abstr 11)
23. Hunt SA, Baker DW, Chin MH, et al: ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure): Developed in collaboration with the International Society for Heart and Lung Transplantation, endorsed by the Heart Failure Society of America. Circulation 104:2996-3007, 2001
24. Packer M, Coats AJS, Fowler MB, et al: Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344:1651-1658, 2001
25. The SOLVD Investigators: Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 327:685-691, 1992
26. Cardinale D, Colombo A, Sandri MT, et al: Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 114:2474-2481, 2006